292 related articles for article (PubMed ID: 24001947)
1. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.
Parent M; Nouvel C; Koerber M; Sapin A; Maincent P; Boudier A
J Control Release; 2013 Nov; 172(1):292-304. PubMed ID: 24001947
[TBL] [Abstract][Full Text] [Related]
2. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
3. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
[TBL] [Abstract][Full Text] [Related]
5. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
6. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
Dong WY; Körber M; López Esguerra V; Bodmeier R
J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
[TBL] [Abstract][Full Text] [Related]
7. Review: approaches to develop PLGA based in situ gelling system with low initial burst.
Ahmed T
Pak J Pharm Sci; 2015 Mar; 28(2):657-65. PubMed ID: 25730797
[TBL] [Abstract][Full Text] [Related]
8. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.
Ahmed TA; Ibrahim HM; Ibrahim F; Samy AM; Kaseem A; Nutan MT; Hussain MD
J Pharm Sci; 2012 Oct; 101(10):3753-62. PubMed ID: 22753324
[TBL] [Abstract][Full Text] [Related]
9. Phase separation of in situ forming poly (lactide-co-glycolide acid) implants investigated using a hydrogel-based subcutaneous tissue surrogate and UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2017 Oct; 145():682-691. PubMed ID: 28803207
[TBL] [Abstract][Full Text] [Related]
10. An in vitro gel-based system for characterizing and predicting the long-term performance of PLGA in situ forming implants.
Li Z; Mu H; Weng Larsen S; Jensen H; Østergaard J
Int J Pharm; 2021 Nov; 609():121183. PubMed ID: 34653562
[TBL] [Abstract][Full Text] [Related]
11. A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery.
Yehia SA; Elshafeey AH; Elsayed I
J Liposome Res; 2012 Jun; 22(2):128-38. PubMed ID: 22091557
[TBL] [Abstract][Full Text] [Related]
12. Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?
Parent M; Boudier A; Dupuis F; Nouvel C; Sapin A; Lartaud I; Six JL; Leroy P; Maincent P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):640-9. PubMed ID: 23954508
[TBL] [Abstract][Full Text] [Related]
13. Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone.
Stein S; Auel T; Kempin W; Bogdahn M; Weitschies W; Seidlitz A
Eur J Pharm Biopharm; 2018 Jun; 127():270-278. PubMed ID: 29490233
[TBL] [Abstract][Full Text] [Related]
14. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization.
Camargo JA; Sapin A; Nouvel C; Daloz D; Leonard M; Bonneaux F; Six JL; Maincent P
Drug Dev Ind Pharm; 2013 Jan; 39(1):146-55. PubMed ID: 22397675
[TBL] [Abstract][Full Text] [Related]
15. Delivery of radix ophiopogonis polysaccharide via sucrose acetateisobutyrate-based in situ forming systems alone or combined with itsmono-PEGylation.
Wang L; Zheng X; Wu F; Shen L; Lin X; Feng Y
Drug Deliv; 2018 Nov; 25(1):267-277. PubMed ID: 29334805
[TBL] [Abstract][Full Text] [Related]
16. Controlled delivery of aspirin: effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems.
Tang Y; Singh J
Int J Pharm; 2008 Jun; 357(1-2):119-25. PubMed ID: 18329202
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of suspoemulsions for in situ-forming polymeric microspheres and controlled release of progesterone.
Turino LN; Mariano RN; Mengatto LN; Luna JA
J Microencapsul; 2015; 32(6):538-46. PubMed ID: 26218541
[TBL] [Abstract][Full Text] [Related]
18. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
Liu SQ; Tong YW; Yang YY
Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
[TBL] [Abstract][Full Text] [Related]
19. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability.
Schoenhammer K; Petersen H; Guethlein F; Goepferich A
Int J Pharm; 2009 Apr; 371(1-2):33-9. PubMed ID: 19135512
[TBL] [Abstract][Full Text] [Related]
20. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process.
Kempe S; Metz H; Mäder K
J Control Release; 2008 Sep; 130(3):220-5. PubMed ID: 18611421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]